Carolina Mazeda, Natacha Oliveira, Catarina Abreu, Vanessa Fraga, Isabel Maduro, André Saraiva, Luís Inês, Carla Ferreira, Ana Margarida Correia, Rafaela Nicolau, Filipa Farinha, Ingrid Villanueva, Diogo Jesus, Pedro Abreu, Agna Neto, Joana Silva Dinis, Anabela Barcelos
OBJECTIVES: Anti-SSA autoantibodies can be differentiated according to their antigenic target proteins as anti-Ro60 (60 kDa) or anti-Ro52 (52 kDa). Anti-SSA(Ro60) antibodies are clearly associated with connective tissue diseases (CTD), but the clinical significance of anti-SSA(Ro52) antibodies remains unclear. The aim of the present study was to analyse the disease phenotype of patients with anti-Ro52 and/or anti-Ro60 antibodies. METHODS: A multicentre, cross-sectional study was carried out of positive anti-Ro52 and/or Ro60 antibodies patients followed at 10 Rheumatology centres from January 2018 until December 2021...
March 26, 2024: Clinical and Experimental Rheumatology